-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2011, the treatment pattern of metastatic melanoma has undergone tremendous changes
Since 2011, the treatment pattern of metastatic melanoma has undergone tremendous changes
During the study period, a total of 2199 patients were registered in the DMTR database
During the study period, a total of 2199 patients were registered in the DMTR database
In the entire study population, the 12-month relapse-free survival rate was 70.
RFS
In AJCC-7 stage IIIA patients, the 12-month recurrence-free survival rate was 87.
In AJCC-7 stage IIIA patients, the 12-month recurrence-free survival rate was 87.
Multivariate analysis of related factors
The one-year follow-up group included 367 patients who were followed up for at least 12 months or died within 12 months
The one-year follow-up group included 367 patients who were followed up for at least 12 months or died within 12 months
224 patients (61.
The 12-month RFS rate of patients in the 1-year follow-up group was 69.
In summary, studies have shown that in daily practice, adjuvant anti-PD -1 treatment after resection of stage III/IV melanoma shows a slightly higher toxicity rate and more frequent premature discontinuation, but compared with clinical studies, RFS The rates are similar
Original source:
de Meza MM, Ismail RK, Rauwerdink D, et al.
Adjuvant treatment for melanoma in clinical practice-Trial versus reality.
Eur J Cancer.
2021 Sep 29:S0959-8049(21)00575-X.
doi: 10.
1016/j.
ejca .
2021.
08.
044.
Epub ahead of print.
PMID: 34600790.
Adjuvant treatment for melanoma in clinical practice-Trial versus reality.
Eur J Cancer.
2021 Sep 29:S0959-8049(21)00575-X.
doi: 10.
1016/j.
ejca .
2021.
08.
044.
Epub ahead of print.
PMID: 34600790.
Leave a message here